Clinical Trials on Advanced Malignant Neoplasm

Total 107248 results

University of Southern California
National Cancer Institute (NCI)

Terminated

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage... and other conditions
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
Bayer

Completed

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma | Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma | Advanced Recurrent Serous Ovarian Cancer | Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

United States, Sweden, Netherlands, United Kingdom, Finland
National Cancer Institute (NCI)

Terminated

EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer

Primary Peritoneal Cavity Cancer | Malignant Ascites | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Localized Malignant Mesothelioma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Advanced Malignant Tumors Lymphomas

United States
Amgen

Completed

A Phase II Study to Treat Advanced Malignant Glioma

Advanced Malignant Glioma
Shenzhen SiBiono GeneTech Co.,Ltd

Unknown

rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors

Advanced Malignant Thyroid Tumors

China
AstraZeneca

Completed

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability (OAK)

Safety and Tolerability, | Advanced Solid Malignancy, | Pharmacokinetics, Pharmacodynamics, | Tumour Response,

United Kingdom, Netherlands
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
Chinese Medical Doctor Association

Unknown

The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey (Sprit)

Colorectal Cancer | Advanced Malignant Neoplasm

China
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
OHSU Knight Cancer Institute
Oregon Health and Science University; Eisai Inc.

Active, not recruiting

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

Malignant Solid Neoplasm | Liposarcoma | Malignant Abdominal Neoplasm | Malignant Retroperitoneal Neoplasm | Malignant Scrotal Neoplasm | Malignant Spermatic Cord Neoplasm

United States
Assistance Publique - Hôpitaux de Paris
Federation Francophone de Cancerologie Digestive; UNICANCER; Merck Serono S.A... and other collaborators

Unknown

Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer (ECKINOXE)

Colon Cancer | Locally Advanced Malignant Neoplasm

France
Cancer Institute and Hospital, Chinese Academy...

Unknown

Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer

Locally Advanced Malignant Neoplasm

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma

Canada
National Cancer Institute (NCI)

Recruiting

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Mahatma Gandhi Institute of Medical Sciences

Recruiting

Registry Trial to Evaluate the Safety and Efficacy of Hyperthermia in Locally Advanced Cancers (RESHMART)

Locally Advanced Malignant Neoplasm

India
National Cancer Institute (NCI)

Completed

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
InnoPharmax Inc.

Completed

Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas

Advanced Solid Malignancies | Malignant Lymphomas

Taiwan
National Cancer Institute (NCI)

Active, not recruiting

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma (MESO-PRIME)

Advanced Malignant Pleural Mesothelioma

United Kingdom
National Cancer Institute (NCI)

Suspended

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

Refractory Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Daiichi Sankyo, Inc.

Completed

Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors

Advanced Solid Malignant Tumors | Advanced Ovarian Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Cutaneous Melanoma | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm | Recurrent Lip and Oral Cavity Carcinoma | Recurrent Malignant Endocrine... and other conditions

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
Second Military Medical University

Unknown

Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract

Advanced Biliary Tract Malignant Tumor

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Mesothelioma, Malignant | Mesothelioma, Malignant Pleural | Mesothelioma Malignant Advanced

China
AGC Biologics S.p.A.

Completed

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (NGR019)

Advanced Malignant Pleural Mesothelioma

Italy, Germany, Russian Federation

Clinical Trials on Advanced Malignant Neoplasm

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations